STOCK TITAN

Roivant Sciences Ltd - ROIV STOCK NEWS

Welcome to our dedicated news page for Roivant Sciences (Ticker: ROIV), a resource for investors and traders seeking the latest updates and insights on Roivant Sciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Roivant Sciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Roivant Sciences's position in the market.

Rhea-AI Summary
Roivant (Nasdaq: ROIV) will host a live conference call and webcast on November 13, 2023, to report its Q2 2023 financial results and provide a business update. The conference call will be accessible via phone registration and the webcast will be available on the Roivant website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.25%
Tags
conferences earnings
-
Rhea-AI Summary
Roche has entered into a definitive agreement with Roivant to acquire Telavant Holdings, gaining the rights to develop and commercialize RVT-3101, a novel TL1A directed antibody for the treatment of inflammatory bowel disease. Roche will pay a purchase price of $7.1 billion upfront and a near-term milestone payment of $150 million. The agreement also includes an option for a global collaboration with Pfizer on a next-generation p40/TL1A directed bispecific antibody.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.02%
Tags
-
Rhea-AI Summary
Lokavant receives $8 million investment from Mitsui & Co. Ltd. to expand its AI-optimized platform in the APAC region. Lokavant to open new APAC headquarters in Tokyo. Mitsui pledges operational support for business development and product localization. Lokavant has raised a total of $29 million in funding. Lokavant's platform provides significant value to pharmaceutical sponsors and CROs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.9%
Tags
Rhea-AI Summary
IMVT-1402 subcutaneous doses showed dose-dependent reductions in IgG with no adverse effects on serum albumin or LDL-C levels. Initial data supports IMVT-1402 as a potential best-in-class FcRn inhibitor. Mean total IgG reduction from baseline in the 300 mg MAD cohort was 63%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
21.55%
Tags
-
Rhea-AI Summary
Roivant completes redemption of outstanding warrants at $0.10 per warrant
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.65%
Tags
none
-
Rhea-AI Summary
Roivant announces the Redemption Fair Market Value for its outstanding public and private placement warrants. The Redemption Fair Market Value is $11.35 per warrant. Holders who exercise their warrants on a cashless basis will receive approximately 0.2495 common shares per warrant. The redemption price for the warrants is $0.10 per warrant. The warrants will cease trading on the redemption date.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.82%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.21%
Tags
-
Rhea-AI Summary
Roivant (Nasdaq: ROIV) will host a conference call on August 14, 2023, to report Q2 2023 financial results and provide a business update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.78%
Tags
conferences earnings
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.62%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.19%
Tags
Roivant Sciences Ltd

Nasdaq:ROIV

ROIV Rankings

ROIV Stock Data

8.82B
423.13M
20.63%
62.12%
3.84%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
UK
London

About ROIV

roivant is a global healthcare company focused on rapidly developing innovative medicines. we believe that the key to unlocking innovation in drug discovery and drug commercialization is to reduce the time and cost of the drug development process. we solve this problem by building vants – nimble, entrepreneurial biotech companies with a unique approach to sourcing talent, aligning economic incentives, and deploying technology to drive greater efficiency in pharma r&d; and commercialization. the goal of our model is to ensure that important medicines rapidly reach patients who suffer from serious diseases. we focus on disease areas where the magnitude of r&d; investment from industry is disproportionately low relative to societal medical needs. we also launch new vants to directly improve the process of developing and commercializing new medicines. our pipeline spans multiple therapeutic areas through partnerships with academic institutions and biopharmaceutical companies, including tak